NVIV - インビボ・セラピュ―ティクス・ホ―ルディングス （InVivo Therapeutics Holdings Corp.） インビボ・セラピュ―ティクス・ホ―ルディングスNVIVのチャート
NVIVの企業情報
| symbol | NVIV |
|---|---|
| 会社名 | InVivo Therapeutics Holdings Corp （インビボ・セラピュ―ティクス・ホ―ルディングス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 InVivo Therapeutics Holdings Corp. formerly Design Source Inc. is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company''s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI. インビボ・セラピュ―ティクス・ホ―ルディングスは、米国のバイオテクノロジ―研究会社。脊髄損傷治療のために生体適合物質技術を開発する。当社の技術は、チルドレンズ・メディカルセンタ―社とマサチュ―セッツ工科大学の下で許諾される知的所有権などを取り入れている。開発中の製品は、脊柱に埋め込む生体再吸収性ポリマ―など。 about invivo therapeutics invivo therapeutics holdings corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. the company was founded in 2005 with proprietary technology co-invented by robert langer, sc.d., professor at massachusetts institute of technology, and joseph p. vacanti, m.d., who then was at boston children’s hospital and who now is affiliated with massachusetts general hospital. in 2011, the company earned the david s. apple award from the american spinal injury association for its outstanding contribution to spinal cord injury medicine. in 2015, the company’s investigational neuro-spinal scaffold received the 2015 becker’s healthcare spine device award. the publicly-traded company is headquartered in cambridge, ma. for more details, visit www.invivotherapeutics.com. about the neuro-spinal scaffold™ following acute spinal cord injury, surgical implantation of the biodegradable neuro-spinal scaffold wi |
| 本社所在地 | One Kendall Square Suite B14402 Cambridge MA 02139 USA |
| 代表者氏名 | Ann Merrifield アンメリフィールド |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 617-863-5524 |
| 設立年月日 | 37712 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 12人 |
| url | www.invivotherapeutics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/nviv |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -18.45300 |
| 終値（lastsale） | 2.03 |
| 時価総額（marketcap） | 15759742.6 |
| 時価総額 | 時価総額（百万ドル） 18.62910 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -3.36090 |
| 当期純利益 | 当期純利益（百万ドル） -31.73700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Invivo Therapeutics Holdings Corp revenues was not reported. Net loss increased 39% to $17.7M. Higher net loss reflects Derivatives gain (loss) decrease from $795K (income) to $10.2M (expense) Interest income decrease of 29% to $77K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$9.91 to -$90.95. |
NVIVのテクニカル分析
NVIVのニュース
Ocean Biomedical, Avenue top healthcare gainers; InVivo, Akebia lead losers'' pack 2023/03/09 15:01:05 Seeking Alpha
Ocean Biomedical OCEA +57%. Avenue Therapeutics (ATXI) +21%. InVivo Therapeutics NVIV -49%. Akebia Therapeutics (AKBA) -22%.
InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury 2023/03/09 13:55:00 Wallstreet:Online
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCI), today announced topline results from the company’s INSPIRE 2.0 study, which was designed to evaluate the safety and probable benefit of InVivo’s investigational Neuro-Spinal Scaffold, a bioresorbable scaffold-based
Is the InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) stock an investment opportunity? 2022/11/18 17:00:00 US Post News
InVivo Therapeutics Holdings Corp. (NVIV)’s stock has witnessed a price hike of 3.20% from the previous close with its current price standing at $2.58. Its current price is -83.87% under its 52-week high of $16.00 and 28.36% more than its 52-week low of $2.01. Based on the past 30-day period, the stock price is -5.74% […]
InVivo Therapeutics Holdings Corp.’s (NASDAQ:NVIV) Stock Is Down -49.25%, But Is It Capable Of A Rally? 2022/10/10 15:30:00 Stocks Register
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) traded at $4.05 at close of the session on Friday, 10/07/22, made a downward move of -49.25% on its previous day’s price. Looking at the stock we see that its previous close was $7.98 and the beta (5Y monthly) reads 1.29 with the day’s price range being $4.02 – $6.05. … InVivo Therapeutics Holdings Corp.’s (NASDAQ:NVIV) Stock Is Down -49.25%, But Is It Capable Of A Rally? Read More »
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) Stock Jumped 46.69% Over A Month – Is There Any Hope Of A Gain? 2022/10/07 16:00:00 Marketing Sentinel
During the recent session, InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV)’s traded shares were 5.16 million, with the beta value of the company hitting 1.11. At the last check today, the stock’s price was $5.00, reflecting an intraday loss of -37.34% or -$2.98. The 52-week high for the NVIV share is $16.50, that puts it down -230.0 … InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) Stock Jumped 46.69% Over A Month – Is There Any Hope Of A Gain? Read More »
Ocean Biomedical, Avenue top healthcare gainers; InVivo, Akebia lead losers'' pack 2023/03/09 15:01:05 Seeking Alpha
Ocean Biomedical OCEA +57%. Avenue Therapeutics (ATXI) +21%. InVivo Therapeutics NVIV -49%. Akebia Therapeutics (AKBA) -22%.
InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury 2023/03/09 13:55:00 Wallstreet:Online
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCI), today announced topline results from the company’s INSPIRE 2.0 study, which was designed to evaluate the safety and probable benefit of InVivo’s investigational Neuro-Spinal Scaffold, a bioresorbable scaffold-based
Is the InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) stock an investment opportunity? 2022/11/18 17:00:00 US Post News
InVivo Therapeutics Holdings Corp. (NVIV)’s stock has witnessed a price hike of 3.20% from the previous close with its current price standing at $2.58. Its current price is -83.87% under its 52-week high of $16.00 and 28.36% more than its 52-week low of $2.01. Based on the past 30-day period, the stock price is -5.74% […]
InVivo Therapeutics Holdings Corp.’s (NASDAQ:NVIV) Stock Is Down -49.25%, But Is It Capable Of A Rally? 2022/10/10 15:30:00 Stocks Register
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) traded at $4.05 at close of the session on Friday, 10/07/22, made a downward move of -49.25% on its previous day’s price. Looking at the stock we see that its previous close was $7.98 and the beta (5Y monthly) reads 1.29 with the day’s price range being $4.02 – $6.05. … InVivo Therapeutics Holdings Corp.’s (NASDAQ:NVIV) Stock Is Down -49.25%, But Is It Capable Of A Rally? Read More »
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) Stock Jumped 46.69% Over A Month – Is There Any Hope Of A Gain? 2022/10/07 16:00:00 Marketing Sentinel
During the recent session, InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV)’s traded shares were 5.16 million, with the beta value of the company hitting 1.11. At the last check today, the stock’s price was $5.00, reflecting an intraday loss of -37.34% or -$2.98. The 52-week high for the NVIV share is $16.50, that puts it down -230.0 … InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) Stock Jumped 46.69% Over A Month – Is There Any Hope Of A Gain? Read More »
Ocean Biomedical, Avenue top healthcare gainers; InVivo, Akebia lead losers'' pack 2023/03/09 15:01:05 Seeking Alpha
Ocean Biomedical OCEA +57%. Avenue Therapeutics (ATXI) +21%. InVivo Therapeutics NVIV -49%. Akebia Therapeutics (AKBA) -22%.
InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury 2023/03/09 13:55:00 Wallstreet:Online
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCI), today announced topline results from the company’s INSPIRE 2.0 study, which was designed to evaluate the safety and probable benefit of InVivo’s investigational Neuro-Spinal Scaffold, a bioresorbable scaffold-based
Is the InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) stock an investment opportunity? 2022/11/18 17:00:00 US Post News
InVivo Therapeutics Holdings Corp. (NVIV)’s stock has witnessed a price hike of 3.20% from the previous close with its current price standing at $2.58. Its current price is -83.87% under its 52-week high of $16.00 and 28.36% more than its 52-week low of $2.01. Based on the past 30-day period, the stock price is -5.74% […]
InVivo Therapeutics Holdings Corp.’s (NASDAQ:NVIV) Stock Is Down -49.25%, But Is It Capable Of A Rally? 2022/10/10 15:30:00 Stocks Register
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) traded at $4.05 at close of the session on Friday, 10/07/22, made a downward move of -49.25% on its previous day’s price. Looking at the stock we see that its previous close was $7.98 and the beta (5Y monthly) reads 1.29 with the day’s price range being $4.02 – $6.05. … InVivo Therapeutics Holdings Corp.’s (NASDAQ:NVIV) Stock Is Down -49.25%, But Is It Capable Of A Rally? Read More »
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) Stock Jumped 46.69% Over A Month – Is There Any Hope Of A Gain? 2022/10/07 16:00:00 Marketing Sentinel
During the recent session, InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV)’s traded shares were 5.16 million, with the beta value of the company hitting 1.11. At the last check today, the stock’s price was $5.00, reflecting an intraday loss of -37.34% or -$2.98. The 52-week high for the NVIV share is $16.50, that puts it down -230.0 … InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) Stock Jumped 46.69% Over A Month – Is There Any Hope Of A Gain? Read More »